Remus Vezan

Title: Remus Vezan and CAR T-Cell Immunotherapy.

Introduction

Remus Vezan is an inventor based in Los Angeles, California. His patent work concerns chimeric antigen receptor (CAR) T-cell immunotherapy, an approach to treating certain cancers.

Latest Patents

Vezan is associated with 1 patent, titled “Methods of Administering Chimeric Antigen Receptor Immunotherapy.” The disclosure describes genetically modified autologous T cells with a CD19-directed CAR for treating relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. The conditions discussed include diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and diffuse large B-cell lymphoma arising from follicular lymphoma. The patent also addresses treatment methods and monitoring after infusion of the T-cell therapy.

Career Highlights

Vezan is associated with Kite Pharma, Inc., a company focused on cell therapies. His listed patent reflects work related to administering and monitoring CAR T-cell treatment.

Collaborations

Rajul Jain is identified as Vezan’s coworker. The provided information does not specify their particular roles or contributions to the patent.

Conclusion

Remus Vezan’s patent work addresses the administration and follow-up of CD19-directed CAR T-cell immunotherapy for certain forms of large B-cell lymphoma.